Diabetes-Induced Renal Vascular Dysfunction Is Normalized by Inhibition of Epidermal Growth Factor Receptor Tyrosine Kinase

Publisher： Karger

E-ISSN： 1423-0135|42|4|284-291

ISSN： 1018-1172

Source： Journal of Vascular Research, Vol.42, Iss.4, 2005-07, pp. : 284-291

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

By  

CANCER, Vol. 121, Iss. 8, 2015-04 ,pp. : E1-E6

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rebiopsy of non–small cell lung cancer patients with acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4325-4332

John Wiley & Sons Inc

Access to resources Recommend Favorite

Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-09 ,pp. : 470-474

Karger

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 91, Iss. 1, 2016-07 ,pp. : 26-34

Karger

Access to resources Recommend Favorite

Management of epidermal growth factor receptor tyrosine kinase inhibitor‐related cutaneous and gastrointestinal toxicities

By  

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, Vol. 14, Iss. 1, 2018-02 ,pp. : 23-31

John Wiley & Sons Inc

Access to resources Recommend Favorite